Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.
Laham Y, Ringelstein-Harlev S, Kurnik D, Fineman R, Yehudai-Ofir D, Bonstein L, Setter-Marco N, Braun E, Ghersin I, Zuckerman T, Beyar-Katz O. Laham Y, et al. Among authors: zuckerman t. Haematologica. 2025 Jan 9. doi: 10.3324/haematol.2024.286714. Online ahead of print. Haematologica. 2025. PMID: 39781629 Free article.
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab.
Fadaos N, Dor YB, Azoulay T, Leiba R, Sharon-Horesh N, Levi T, Horowitz NA, Tzoran I, Lavi N, Beyar-Katz O, Dann EJ, Zuckerman T, Ringelstein-Harlev S. Fadaos N, et al. Among authors: zuckerman t. Ann Hematol. 2024 Dec;103(12):5861-5870. doi: 10.1007/s00277-024-06130-y. Epub 2024 Dec 12. Ann Hematol. 2024. PMID: 39663256
Trial eligibility, treatment patterns and outcome for venetoclax-based therapy in AML: a prospective cohort study.
Wolach O, Levi I, Nachmias B, Tavor S, Amitai I, Ofran Y, Ganzel C, Zuckerman T, Okasha D, Hellmann I, Tadmor T, Dally N, Canaani J, Stemer G, Grunspan M, Berger AJ, Frankel N, Berelovich J, Bleterman A, Barak M, Cohen R, Moshe Y. Wolach O, et al. Among authors: zuckerman t. Blood Adv. 2024 Dec 5:bloodadvances.2024014014. doi: 10.1182/bloodadvances.2024014014. Online ahead of print. Blood Adv. 2024. PMID: 39637307
Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.
McGuirk JP, Metheny L 3rd, Pineiro L, Litzow M, Rowley SD, Avni B, Tamari R, Lazarus HM, Rowe JM, Sheleg M, Rothenstein D, Halevy N, Zuckerman T. McGuirk JP, et al. Among authors: zuckerman t. Bone Marrow Transplant. 2024 Dec 3. doi: 10.1038/s41409-024-02469-y. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39627347 No abstract available.
Acute myeloid leukemia drug tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.
Morgenstern Y, Lee J, Na Y, Lieng BY, Ly NS, Gwynne WD, Hurren R, Ma L, Ling D, Gronda M, Arruda A, Frisch A, Zuckerman T, Ofran Y, Minden MD, Zhang L, O'Brien C, Quaile AT, Montenegro-Burke JR, Schimmer AD. Morgenstern Y, et al. Among authors: zuckerman t. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286018. Online ahead of print. Haematologica. 2024. PMID: 39568440 Free article.
Neutrophil-to-Lymphocyte Ratio as a Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis.
Keret S, Kaly L, Schett G, Bergmann C, Feldman E, Zuckerman T, Yehudai-Ofir D, Shouval A, Awisat A, Rosner I, Rozenbaum M, Boulman N, Sawaed A, Hardak E, Henes J, Slobodin G, Rimar D. Keret S, et al. Among authors: zuckerman t. Rheumatology (Oxford). 2024 Nov 1:keae606. doi: 10.1093/rheumatology/keae606. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39485492
Eosinophilic Pleocytosis in the Cerebrospinal Fluid following CAR-T Cell Therapy for Central Nervous System Lymphoma: A Case for Warning?
Abu Ata M, Henig I, Yehudai-Ofir D, Tzoran I, Ringelstein-Harlev S, Inbar T, Slouzkey I, Karmona Fintuch M, Stern A, Stanevsky O, Weiler-Sagie M, Zohar Y, Livneh I, Merhav G, Eran A, Zuckerman T, Katz OB. Abu Ata M, et al. Among authors: zuckerman t. Acta Haematol. 2024 May 24:1-8. doi: 10.1159/000539354. Online ahead of print. Acta Haematol. 2024. PMID: 38781944
Cardiac safe hematopoietic stem cell transplantation protocol for systemic sclerosis with myocarditis- a two-step approach.
Keret S, Chutko B, Dobrecky-Mery I, Wolak A, Hardak E, Slobodin G, Shouval A, Israel H, Zuckerman T, Yehudai-Ofir D, Farge D, Rimar D. Keret S, et al. Among authors: zuckerman t. Rheumatology (Oxford). 2024 May 13:keae268. doi: 10.1093/rheumatology/keae268. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38741216 No abstract available.
145 results